BioSpace News Archive

Lentiviral vectors find utilization as a medium to make a delivery of foreign genetic material into a separate cell. Making use of a type of retrovirus, a lentivirus, these vectors are produced.

According to the report, the global customized procedure trays market was valued at ~US$ 2 Bn in 2018 and is projected to expand at a high CAGR during the forecast period.

Cathepsin B is an important mediator of inflammation and programmed cell death in individual cells. It has a role in inducing cell dissolution and recycling of cellular organelles.

ONK Therapeutics Ltd, an innovative natural killer cell therapy company, announced that it has been awarded an Innovation Partnership Programme grant by Enterprise Ireland to fund collaborative research at Trinity College Dublin, Ireland, led by Dr. David Finlay to optimize the metabolism and engineering of NK cells for improved cancer therapies.

One Medical, a leading national technology-powered primary care organization, announced the appointment of Scott C. Taylor to its board of directors.

bioSyntagma®, Inc unveiled the world’s first high-plex multi-omic spatial workflow designed for clinical samples and diagnostic applications.

Madrigal Pharmaceuticals, Inc, a clinical- stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis, announced its management team will participate in two upcoming virtual investor conferences

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced it has acquired Transplant Hero LLC, a New York-based provider of a mobile application supporting the needs of transplant patients.

Odyssey Group International, Inc., a technology and asset acquisition company focused on developing unique, life-saving medical products, announced that its CEO, Michael Redmond, and Executive VP of Drug Development, Dr. Jake VanLandingham will present at the 2021 LD Micro Invitational XI Investor Conference.

Summit Therapeutics Inc. is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US markets open on June 28, according to a preliminary list of additions posted by FTSE Russell.